Back

FDA accepts Takeda’s zasocitinib application for psoriasis under priority review

Verifying
  • FDA accepted Takeda’s zasocitinib application for moderate-to-severe plaque psoriasis.
  • The New Drug Application received priority-review status from the U.S. regulator.
  • Zasocitinib is presented as having potential to redefine oral treatment expectations.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.